Research & market products
built for sponsors.
Four distinct evidence pathways — each designed for different clinical, regulatory, and commercial objectives. Start with one. Evolve as your evidence needs grow.
Choose your path. Or take them all.
Sponsors can engage one pathway or layer multiple over time — Celéri's infrastructure means you never have to rebuild from scratch.
Commercial Insights Registry™
A practice-embedded registry capturing patient-reported outcomes as part of routine care — no IRB, no site contracts, fast deployment. Built for market adoption and outcomes storytelling.
- No IRB oversight — operates as a commercial quality & insights program
- Flexible PRO sets aligned to your commercial strategy
- Supports post-market surveillance and thought leadership
- Real-time dashboards for internal teams and participating practices
- Broad site participation from day one of launch
Fast deployment, broad site participation, and longitudinal outcomes that support market growth and value narratives.
Regulatory-Grade Evidence Cohort™
A prospective, observational cohort with IRB exemption and direct-to-patient engagement. Designed to meet FDA and payer expectations for real-world evidence — without the site burden of a traditional study.
- Direct-to-patient eConsent, SMS/email PRO collection
- No site staff burden; no site contracts required
- Fixed, protocol-defined endpoints protect downstream use
- Designed to meet FDA and payer RWE expectations
- Publication-ready dataset output
Clean, defensible real-world evidence — quickly — without the friction of traditional studies.
Traditional Prospective Study
Full protocol development, IRB approval, and site activation conducted with Celéri's pain-specialized investigator network. Built for the highest level of regulatory and scientific scrutiny.
- Full protocol development, IRB approval & site activation
- Site-collected clinical and patient-reported data
- Structured monitoring, data management & audit trails
- Suitable for IDE support, PMA supplements, and high-impact publications
- Pain-specialized investigator network
Gold-standard clinical evidence with the rigor required for regulatory and scientific scrutiny.
PainRWD™ Science Cloud
Access to a large, de-identified real-world pain dataset with longitudinal PROs, procedures, diagnoses, and utilization signals. Immediate insights at scale — without waiting for new data collection.
- Large de-identified real-world pain dataset
- Advanced analytics, subgroup analysis & benchmarking
- Supports HEOR, payer dossiers & feasibility assessments
- Can stand alone or enhance prospective and registry studies
- Hypothesis generation and comparator insights
Immediate insights at scale — without waiting for new data collection.
How they work together.
Sponsors often begin with a commercial registry or exempt RWE cohort, then layer in traditional studies or Science Cloud analytics as evidence needs mature — all without rebuilding from scratch.
Launch with Commercial Registry
Deploy Celéri at commercial launch. Capture patient-reported outcomes from every clinical site with no IRB burden. Build your real-world baseline and support physician engagement from day one. See the deployment model →
Add Regulatory-Grade RWE
Layer in the Regulatory-Grade Evidence Cohort™ to generate payer-ready and FDA-aligned datasets — direct to patient, no additional site burden. Your commercial data and RWE data share the same infrastructure.
Escalate to Study or Science Cloud
When label expansion or high-impact publication requires gold-standard rigor, activate a Traditional Prospective Study with Celéri's pain investigator network. Or tap PainRWD™ Science Cloud for comparator benchmarks and HEOR modeling — without starting from zero.
Ready to build your evidence strategy?
Talk to a Celéri evidence strategist. We'll help you identify the right pathway — or combination — for your product and stage.
